Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1144 33 |
Ultima descărcare din IBN: 2024-01-27 01:51 |
Căutarea după subiecte similare conform CZU |
615.243.4:616.33-008-08 (1) |
Medicamentele potrivit acţiunii lor principale (395) |
Patologia sistemului digestiv. Tulburări ale tubului alimentar (1732) |
SM ISO690:2012 GHICAVÂI, Victor, BACINSCHI, Nicolae, PODGURSCHI, Lilia, HELAL, Nashif. Inhibitorii pompei protonice – realizări, probleme şi perspective prin prisma farmacologiei clinice.. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2016, nr. 1(50), pp. 337-341. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 1(50) / 2016 / ISSN 1857-0011 | ||||||
|
||||||
CZU: 615.243.4:616.33-008-08 | ||||||
Pag. 337-341 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Inhibitorii pompei protonice constituie baza tratamentului antiulceros cu eficacitate demonstrată şi capacitate de eradicare a infecţiei cu H.pylori. În pofida succeselor obţinute survin unele probleme, precum dezvoltarea rezistenţei, efi cacitatea insufi cientă, pentru rezolvarea cărora se sintetizează medicamente noi şi promedicamente, se separă enantomerii, se obţin forme medicamentoase cu eliberare rapidă, prelungită şi controlată, se elaborează preparate combinate. |
||||||
Cuvinte-cheie inhibitorii pompei protonice, farmacogenetica, farmacodinamia, farmacocinetice, efect antisecretor |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-46665</cfResPublId> <cfResPublDate>2016-04-21</cfResPublDate> <cfVol>50</cfVol> <cfIssue>1</cfIssue> <cfStartPage>337</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/46665</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Inhibitorii pompei protonice – realizări, probleme şi perspective prin prisma farmacologiei clinice.</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>inhibitorii pompei protonice; farmacodinamia; farmacocinetice; farmacogenetica; efect antisecretor</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'>Inhibitorii pompei protonice constituie baza tratamentului antiulceros cu eficacitate demonstrată şi capacitate de eradicare a infecţiei cu H.pylori. În pofida succeselor obţinute survin unele probleme, precum dezvoltarea rezistenţei, efi cacitatea insufi cientă, pentru rezolvarea cărora se sintetizează medicamente noi şi promedicamente, se separă enantomerii, se obţin forme medicamentoase cu eliberare rapidă, prelungită şi controlată, se elaborează preparate combinate. </cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'>Proton pump inhibitors - achievements, problems and prospects in terms of clinical pharmacology Proton pump inhibitors are the basis of treatment of ulcer disease with demonstrated efficacy and ability to enhance the eradication of Helicobacter pylori infection. Despite these successes, however, the problems remain like: resistance, insufficient efficacy, that for solving of them are created new drugs through formation of enantomers – fast - and slow-release drugs, are created prodrugs and compound drugs. </cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>Ингибиторы протонной помпы – достижения, проблемы и перспективы с точки зрения клинической фармакологии Ингибиторы протонной помпы составляют основу терапии язвенной болезни с доказанной эффективностью и способностью усиливать эррадикацию хеликобактерной инфекции. Несмотря на достигнутые успехи возникают ряд проблем (резистентность, недостаточная эффективность лечения) для решения которых создаются новые препараты и пролекарства, выделяются энантомеры, разрабатываются лекарственные формы с немедленным или пролонгированным и контролируемым освобождением активных компонентов, внедряются комбинированные препараты. </cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11721</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10648</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-22820</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-47664</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11721</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11721-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> <cfFamilyNames>Ghicavîi</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> <cfFamilyNames>Гикавый</cfFamilyNames> <cfFirstNames>Виктор</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10648</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10648-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> <cfFamilyNames>Bachinsky</cfFamilyNames> <cfFirstNames>N.G.</cfFirstNames> <cfFamilyNames>Бачинский</cfFamilyNames> <cfFirstNames>Николай</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-22820</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-22820-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> <cfFamilyNames>Podgursky</cfFamilyNames> <cfFirstNames>L. A.</cfFirstNames> <cfFamilyNames>Подгурски</cfFamilyNames> <cfFirstNames>Лилия</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-47664</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-47664-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-04-21T24:00:00</cfStartDate> <cfFamilyNames>Helal</cfFamilyNames> <cfFirstNames>Nashif</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>